POZEN Reports First Quarter 2015 Results
MarketWatch In the first quarter of 2015, the Company sold its Pernix Therapeutics Holdings, Inc. common stock warrants resulting in cash proceeds of $2.5 million. As the cash proceeds were less than the Black-Sholes value of the warrants in our balance sheet at … |